Warren , Richard, April Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup, Sundeep Kundu, Renata Kisa, Subhashis Banerjee, and Andrew Blauvelt. 2022. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 6 (2):s4. https://doi.org/10.25251/skin.6.supp.4.